1. Home
  2. Medical News
  3. Pulmonary Medicine
advertisement

Cryobiopsy Aided ILD Diagnosis in 81% With Severe Impairment

Illustrated lungs with subtle interstitial changes representing suspected interstitial lung disease and severe lung function
11/06/2026

Key Takeaways

  • Patients with severe lung-function impairment were a minority of TBLC recipients evaluated for suspected ILD at the Heidelberg center.
  • TBLC contributed to the final multidisciplinary diagnosis at similar rates in the severe and less impaired groups.
  • Pneumothorax rates did not differ significantly between groups, but this does not establish equivalent safety.
  • Severe bleeding rates also did not differ significantly, without establishing equivalent safety.
Suspected interstitial lung disease (ILD) can make the balance between tissue diagnosis and procedural safety particularly difficult when lung function is markedly reduced. Current guidelines frequently exclude patients with severe impairment from cryobiopsy because of safety concerns. For patients who might otherwise benefit from tissue sampling, the questions are whether biopsy contributes to a final diagnosis and what complications accompany the procedure.

Investigators retrospectively reviewed consecutive patients who underwent transbronchial lung cryobiopsy (TBLC) for suspected ILD at Thoraxklinik Heidelberg, University Hospital Heidelberg, from November 2017 through December 2021. The cohort included 396 recipients, of whom 43 (10.9%) had severe lung-function impairment.

Severe impairment meant forced vital capacity (FVC) <50% predicted and/or single-breath diffusing capacity for carbon monoxide (DLCO-SB) <35% predicted; the other biopsy recipients formed the less impaired comparison group. Investigators assessed procedural complications and TBLC's contribution to the final diagnosis following post-biopsy multidisciplinary discussion.

TBLC contributed to a final diagnosis following multidisciplinary review in 318/396 patients (80%) overall. Its contribution was recorded in 81% of severely impaired recipients and 80% of those with less impairment. This measure reflects contribution to a multidisciplinary diagnosis, not standalone histopathology accuracy or an effect on treatment.

Pneumothorax occurred in 11.6% of severely impaired recipients versus 14.7% of less impaired recipients. Severe bleeding requiring endoscopic hemostasis occurred in 25.6% versus 17.8%, respectively. Neither group difference was statistically significant. Chest tubes were required in 33 cases overall. No procedure-related complication required surgery.

The severely impaired group was small, and this retrospective comparison included only patients selected for biopsy at one Heidelberg center. Patients not selected for TBLC were not represented. These constraints limit conclusions about comparative complication risk and applicability to the wider population with suspected ILD and severely reduced lung function.

The authors concluded that TBLC may be a diagnostic option for carefully selected patients with severe pulmonary impairment at experienced centers following individual risk–benefit assessment.

Clinician Questions

When did multidisciplinary review occur around cryobiopsy for suspected ILD at Heidelberg?

Investigators at Thoraxklinik Heidelberg, University Hospital Heidelberg, discussed every suspected ILD case before and again after transbronchial lung cryobiopsy; they assessed complications and diagnostic contribution following the post-biopsy discussion.

How long were complications monitored after cryobiopsy in patients with severe ILD-related lung impairment?

Complications were captured only during the procedure and inpatient observation, which generally extended to the day after biopsy; there was no systematic post-discharge follow-up, so delayed events may have been missed.

Recommended Reading

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free